4th Quarter - Report

NATIONAL ORGANIZATION FOR RARE DISORDERS, INC. (NORD) for NATIONAL ORGANIZATION FOR RARE DISORDERS INC (NORD)

Firm
Client
Income
—
Expenses
$70,000
Expense method
A: Lobbying Disclosure Act definitions

What was lobbied

4 issue areas, each in the filer's own words, with who lobbied on it and where.

Budget/Appropriations BUD

Appropriations for patients with rare diseases. Food and Drug Administration Appropriations. National Institutes of Health (NIH) Appropriations.

LobbyistCovered position, as disclosed
MICHELLE ADAMS —
MELANIE SWICK BUZZELLI —

Contacted: Health & Human Services, Dept of (HHS); SENATE; Centers For Medicare and Medicaid Services (CMS); Food & Drug Administration (FDA); Natl Institutes of Health (NIH); HOUSE OF REPRESENTATIVES

Medicare/Medicaid MMM

Medicare issues impacting patients with rare diseases. Medicare Part D Program. Section 1115 Waivers. Section 1332: State Innovation Waivers. CMS-2019-0100-0562: Medicare and Medicaid Programs: CY 2020 Home Health Prospective Payment System Rate Update; Home Health Value-Based Purchasing Model; Home Health Value-Based Purchasing Model; Home Health Quality Reporting Requirements; and Home Infusion Therapy Requirements. S.J.Res.52: A joint resolution providing for congressional disapproval under chapter 8 of title 5, United States Code, of the rule submitted by the Secretary of the Treasury and the Secretary of Health and Human Services relating to "State Relief and Empowerment Waivers".

LobbyistCovered position, as disclosed
MICHELLE ADAMS —
RACHEL L. SHER —
MELANIE SWICK BUZZELLI —

Contacted: SENATE; Centers For Medicare and Medicaid Services (CMS); HOUSE OF REPRESENTATIVES; Natl Institutes of Health (NIH); Food & Drug Administration (FDA); Health & Human Services, Dept of (HHS)

Bills named: S.J.Res. 52 (116th)

Health Issues HCR

Health issues impacting patients with rare diseases. H.R.4228: Rare disease Advancement, Surveillance Research, and Education (RARE) Act of 2019. Rare Cancer. Step Therapy. H.R.2279/S.2546: Safe Step Act. Newborn Screening. H.R.2507/S.2158: Newborn Screening Saves Lives Reauthorization Act of 2019. H.R.1379/S.560: Ensuring Lasting Smiles Act. Pediatric Research Equity Act (PREA). Biosimilars. Genetic Testing. Clinical Trials. Institutional Review Boards. Medical Devices. Medical Foods. H.R.2501: Medical Nutrition Equity Act of 2019. Public Law No: 111-148: The Patient Protection and Affordable Care Act. S.1895: Lower Health Care Costs Act. Surprise Medical Billing. Dr. Hahn's Confirmation.

LobbyistCovered position, as disclosed
MICHELLE ADAMS —
ROSE AVELLINO GALLAGHER —
RACHEL L. SHER —
MELANIE SWICK BUZZELLI —

Contacted: Natl Institutes of Health (NIH); SENATE; HOUSE OF REPRESENTATIVES; Centers For Medicare and Medicaid Services (CMS); Health & Human Services, Dept of (HHS); Food & Drug Administration (FDA)

Bills named: H.R. 4228 (116th), S. 1895 (116th), H.R. 2501 (116th), H.R. 2507 (116th), H.R. 1379 (116th), H.R. 2279 (116th), S. 560 (116th), S. 2158 (116th), S. 2546 (116th)

Pharmacy PHA

Pharmaceutical issues impacting patients with rare diseases. Orphan Drug Act. Drug Pricing. H.R.3: Elijah E. Cummings Lower Drug Costs Now Act. FDA Patient-Focused Drug Development (PFDD) Draft Guidance. H.R.4712: Fairness in Orphan Drug Exclusivity Act.

LobbyistCovered position, as disclosed
MICHELLE ADAMS —
ROSE AVELLINO GALLAGHER —
RACHEL L. SHER —
MELANIE SWICK BUZZELLI —

Contacted: Natl Institutes of Health (NIH); Food & Drug Administration (FDA); Centers For Medicare and Medicaid Services (CMS); HOUSE OF REPRESENTATIVES; SENATE; Health & Human Services, Dept of (HHS)

Bills named: H.R. 3 (116th), H.R. 4712 (116th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.